One-year Incidence and Standardized Mortality Rates for Esophageal Squamous Cell Carcinoma in Uganda

Background: Little is known about the survival of patients with esophageal squamous cell cancer in resource limited settings.Objectives: We sought to determine the incidence of one-year all-cause mortality and age-standardized mortality rates for esophageal squamous cell carcinoma in Uganda.Methods: Prospective cohort of 92 participants with histologically confirmed esophageal squamous cell cancer at Mbarara Regional Referral Hospital, southwestern Uganda. Participants were enrolled between January 2018 and March 2020 and followed until death. We used Kaplan-Meier methods to determine all-cause mortality and median survival time; Cox regression to determine predictors of survival; and determined age-standardized mortality rates (SMR) using the WHO standard population. Results: All 92 participants contributed a total 353.8 months at risk, 89 (96.7%) died representing an incidence rate of 251.5 (95% CI 204.3, 309.6) per 1000 person-months. The difference in the one-year risk of all-cause mortality among men and women was negative 6.4 percentage points. The overall SMR was 9.96 (95%CI 7.63, 12.29) per 100,000 and median survival time was 3.03 (95% CI 2.60, 3.47), shortest (1.77 months) among men younger than 45 and longest (7.77 months) among women aged 75 years or greater. In a fully adjusted model, high socioeconomic status predicted longer survival while increasing age and low socioeconomic status predicted shorter survival.Conclusion: After diagnosis, the one-year incidence rates of all-cause mortality and age-standardized mortality rates among ESCC patients in rural Uganda are high. Initiatives to improve access to oncology care for diagnosis and treatment should be prioritized to improve overall survival.

[1]  A. Asombang,et al.  Systematic review and meta-analysis of esophageal cancer in Africa: Epidemiology, risk factors, management and outcomes , 2019, World journal of gastroenterology.

[2]  Yi-qing Wang,et al.  Novel preoperative nutritional assessment tool and prognostic model for ESCC patients , 2019, Journal of Cancer.

[3]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[4]  J. Lagergren,et al.  Global time trends in the incidence of esophageal squamous cell carcinoma , 2018, Clinical epidemiology.

[5]  D. Christiani,et al.  Population attributable fraction of Esophageal squamous cell carcinoma due to smoking and alcohol in Uganda , 2016, BMC Cancer.

[6]  M. Guo,et al.  The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma , 2016, Clinical Epigenetics.

[7]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[8]  Gary Alan Bass,et al.  Chemoradiotherapy, with adjuvant surgery for local control, confers a durable survival advantage in adenocarcinoma and squamous cell carcinoma of the oesophagus. , 2014, European journal of cancer.

[9]  A. Delpisheh,et al.  Demographic and Histological Predictors of Survival in Patients With Gastric and Esophageal Carcinoma , 2013, Iranian Red Crescent medical journal.

[10]  R. Malekzadeh,et al.  Prognostic Factors for Esophageal Squamous Cell Carcinoma—A Population-Based Study in Golestan Province, Iran, a High Incidence Area , 2011, PloS one.

[11]  Erik Schokkaert,et al.  Direct versus indirect standardization in risk adjustment. , 2009, Journal of health economics.

[12]  D. Parkin,et al.  The evolution of the population-based cancer registry , 2006, Nature Reviews Cancer.

[13]  S. Nag,et al.  Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma--an International Atomic Energy Agency study. , 2001, International journal of radiation oncology, biology, physics.

[14]  C. Falkson,et al.  A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus. , 1998, American journal of clinical oncology.

[15]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[16]  Rafael Lozano,et al.  AGE STANDARDIZATION OF RATES: A NEW WHO STANDARD , 2000 .

[17]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.

[18]  N. Dubrawsky Cancer statistics , 2022 .

[19]  Dataset for the histopathological reporting of oesophageal carcinoma ( 2 nd edition ) February 2007 , 2022 .